Skip to main content

Table 1 Summary of the different experiments done in this study including the objectives of the experiments, treatments (with concentrations) and controls (with vehicles used to dissolve the agonists and antagonists) and the number of animals used in each group

From: Prostaglandin E2 sensitizes the cough reflex centrally via EP3 receptor-dependent activation of NaV 1.8 channels

Treatment/ Pretreatment Objective Control Treatment Groups
Vehicle Concentration 1 Concentration 2 Concentration 3
PGE2 To study the effect of treatment on citric acid-induced cough 10% ethanol in ACSF
(n = 12)
0.3 mg/ml
(n = 8)
0.6 mg/ml
(n = 12)
1 mg/ml
(n = 13)
Sulprostone
Non-selective EP1/EP3 agonist
To study the effect of treatment on citric acid-induced cough 10% DMSO in ACSF
(n = 9)
0.1 mg/ml
(n = 8)
0.3 mg/ml
(n = 7)
1 mg/ml
(n = 9)
ONO-8130
EP1 receptor antagonist
To study the effect of pretreatment on sulprostone-enhanced citric acid-induced cough 70% DMSO in ACSF
 + sulprostone
(1 mg/ml)
(n = 10)
1 mg/mL
 + sulprostone
(1 mg/ml)
(n = 7)
5 mg/mL
 + sulprostone
(1 mg/ml)
(n = 6)
L-798,106
EP3 receptor antagonist
To study the effect of pretreatment on sulprostone-enhanced citric acid-induced cough 70% DMSO in ACSF + sulprostone
(1 mg/ml)
(n = 10)
2.5 mg/mL
 + sulprostone
(1 mg/ml)
(n = 7)
5 mg/mL
 + sulprostone
(1 mg/ml)
(n = 10)
Butaprost
EP2 receptor agonist
To study the effect of treatment on citric acid-induced cough 10% DMSO in ACSF
(n = 11)
0.3 mg/ml
(n = 8)
1 mg/ml
(n = 10)
L-902,688
EP4 receptor agonist
To study the effect of treatment on citric acid-induced cough 10% DMSO in ACSF
(n = 7)
0.3 mg/ml
(n = 9)
1 mg/ml
(n = 8)
JNJ-17203212
TRPV1 channel antagonist
To study the effect of pretreatment on PGE2-enhanced citric acid-induced cough 70% DMSO in ACSF + 
PGE2 (1 mg/ml)
(n = 10)
0.4 mg/mL
 + PGE2 (1 mg/ml)
(n = 10)
1.3 mg/mL
 + PGE2 (1 mg/ml)
(n = 9)
HC-030031
TRPA1 channel antagonist
To study the effect of pretreatment on PGE2-enhanced citric acid-induced cough 5% DMSO in ACSF + 
PGE2 (1 mg/ml)
(n = 8)
0.02 mg/mL + 
PGE2 (1 mg/ml)
(n = 7)
0.05 mg/ml + 
PGE2 (1 mg/ml)
(n = 6)
Combination
JNJ-17203212 + HC-030031
To study the effect of pretreatment on PGE2-enhanced citric acid-induced cough 70% DMSO in ACSF + 
PGE2 (1 mg/ml)
(n = 7)
0.4 + 0.02 mg/mL + PGE2 (1 mg/ml)
(n = 5)
1.3 + 0.05 mg/mL + PGE2 (1 mg/ml)
(n = 6)
Tetrodotoxin (TTX)
Tetrodotoxin-sensitive sodium channel antagonist
To study the effect of pretreatment on PGE2-enhanced citric acid-induced cough 99% ACSF + PGE2  (1 mg/ml)   (n = 7) 0.015 µg/mL + PGE2 (1 mg/ml)
(n = 7)
0.1 µg/mL + 
PGE2 (1 mg/ml)
(n = 5)
A-803467
NaV 1.8 channel antagonist
To study the effect of pretreatment on PGE2-enhanced citric acid-induced cough 70% DMSO in ACSF + 
PGE2 (1 mg/ml)
(n = 6)
5 mg/mL + 
PGE2 (1 mg/ml)
(n = 5)
10 mg/mL + 
PGE2 (1 mg/ml)
(n = 5)